On Oct. 18, 2021, Athenex and the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children’s Hospital and Houston Methodist Hospital announced that the U.S. Patent and Trademark Office has allowed patent claims around its NKT cellular immunotherapy platform.

While similar claims had already been granted in the European Union, these claims were the first allowed on this technology in the U.S.